FDA expedites review of BioMarin's rare-disease drug Vimizim

05/31/2013 | RTT News

The FDA has accepted BioMarin Pharmaceutical's biologics license application for Vimizim, or BMN-110, elosulfase alfa, an experimental treatment for Mucopolysaccharidosis type IVA, also known as Morquio A Syndrome. The enzyme replacement therapy was granted a priority-review status.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA